When Will Generic Ozempic Be Available in the US?

Not this decade, according to the experts quoted by NBC News on May 13, 2026 ^[2]. The FDA has not approved any generic version of Ozempic, according to Drugs.com’s availability record last updated on August 13, 2026 ^[1]. Those experts say Americans are not expected to get generic semaglutide, the active ingredient in Ozempic and Wegovy, until at least the end of 2031 ^[2]. Even that date is uncertain. Arti K. Rai, a professor at Duke University School of Law and a former senior official at the US Patent and Trademark Office, said it “could take much, much longer than that” ^[2]. The advocacy group I-MAK has projected that Novo Nordisk’s stack of secondary patents could block US generics until 2042 ^[2].

The delay is a US-specific problem. India saw multiple generic semaglutide products launch on March 21, 2026, the day Novo Nordisk’s core Indian patent expired ^[8]. Canada became the first G7 country to approve a generic semaglutide on April 28, 2026 ^[5][21]. IQVIA, a health-information company, places the US in the third and largest wave of markets losing exclusivity, after a first wave in 2026 and a second wave of European markets that opens before the US ^[4].

What do the US patents on Ozempic actually show?

The patent protection listing on the Drugs.com availability record for Ozempic includes patent 11,382,957, which covers solid compositions of a GLP-1 agonist with a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. It expires on December 16, 2031 and covers both the drug substance and the drug product ^[1].

Several later-listed patents run well past that date ^[1]:

Patent number	Expiry date	What it covers
11,382,957	December 16, 2031	GLP-1 agonist + SNAC salt solid compositions (drug substance and product)
10,335,462	June 21, 2033	Use of long-acting GLP-1 peptides in dosing regimens
11,033,499	June 19, 2033	Tablet formulation with a GLP-1 peptide and a delivery agent
10,278,923	May 2, 2034	Oral dosing of GLP-1 compounds
10,888,605 and 11,752,198	August 24, 2038	Semaglutide compositions with no more than 0.01% phenol
11,318,191	February 17, 2041	Compositions with no more than 0.1% phenol and above 6.4 mg/ml sodium chloride

Four device patents — 10,357,616 and 10,376,652, expiring January 20, 2026, and 10,220,155 and 11,097,063, expiring July 17, 2026 — have already reached their expiry dates, and the sponsor has requested that they be delisted ^[1].

Beyond that listing, I-MAK counts at least 49 semaglutide patents filed by Novo Nordisk and projects they could keep generics out of the US market until 2042 ^[2]. That projection comes from an advocacy group, not from a court or regulator.

The FDA approval record for Ozempic itself shows a long list of formulations: the original 2MG/1.5ML injection approved December 5, 2017 (now discontinued), followed by approvals on April 9, 2019, March 28, 2022, October 6, 2022, and single-dose strengths on May 5, 2026. Oral tablet strengths of 1.5MG, 4MG, and 9MG were approved December 9, 2024 ^[1].

Why is the US so far behind India and Canada?

It comes down to patent term and patent stacking. Novo Nordisk first applied for a US patent on semaglutide in 2006 ^[2]. The standard length of a US drug patent is 20 years from the filing date, which would have put semaglutide’s protection ending around 2026 ^[2].

The Hatch-Waxman Act of 1984 allows drugmakers to extend a patent by up to five extra years to make up for time lost moving a drug through clinical trials and FDA review. Rai said those five years, stretching the patent from 2026 to 2031, likely stem from the Hatch-Waxman Act ^[2].

On top of that come secondary patents, a tactic known as evergreening. Robin Feldman, a pharmaceutical and intellectual property law expert at UC Law San Francisco, said the semaglutide patents range from the chemical molecules themselves to methods of use for different indications — diabetes, weight loss, and heart disease — to device patents for the delivery mechanisms ^[2].

Feldman’s view is that the extra patents are the whole story for US timing: “Without the additional patents allowed in our patent system, the U.S. would be seeing generic versions within a year of the rest of the world, instead of waiting many more years” ^[2].

The industry pushes back. A Novo Nordisk spokesperson said, “All intellectual property decisions are carefully considered at a global level” ^[2]. Andrew Powaleny, a spokesperson for the industry trade group PhRMA, said medications often have multiple patents because “like any technologically advanced product, they incorporate multiple inventions” ^[2].

Which countries already have generic semaglutide?

Eight markets lose semaglutide exclusivity in 2026, according to IQVIA: Canada, Brazil, China, India, Mexico, Turkey, Saudi Arabia, and South Africa ^[4]. Saudi Arabia is a special case — the local patent was never filed there, so there was no typical period of market protection ^[4].

C&EN reported that the semaglutide patent expires in March 2026 in India, China, and Brazil, and during 2026 in Turkey and Canada ^[3]. Feldman told NBC News that China, Brazil, and South Africa are expected to follow India and Canada with generic approvals ^[2].

The money at stake is enormous. In 2024, Novo Nordisk generated $26 billion in revenue from Wegovy and Ozempic combined, and Eli Lilly’s Mounjaro and Zepbound, which contain tirzepatide, had combined sales of nearly $16 billion ^[3].

What happened in India?

On March 21, 2026, multiple generic semaglutide products launched in India on the day Novo Nordisk’s core Indian patent expired, with the companies proclaiming “Day 1 entry” ^[8]. The launches included ^[8]:

Company	Brand	Indication	Approximate cost
Dr Reddy’s	Obeda	Type 2 diabetes	About INR 4,200 per month
Zydus	Semaglyn, Mashema, Alterme	Type 2 diabetes and obesity	About INR 2,200 per month
Alkem	Semasize, Obesema, Hepaglide	Type 2 diabetes and weight management	From INR 1,800 per month (about INR 450 per week)
Sun Pharma	Noveltreat / Sematrinity	Weight management / type 2 diabetes	INR 900–2,000 per week / INR 750–1,300 per week
Glenmark	GLIPIQ	Type 2 diabetes	INR 325–440 per week (vials)

Dr Reddy’s said it was the first Indian company to receive approval from the Drugs Controller General of India for generic semaglutide ^[8]. Zydus’s products are co-marketed by Lupin under the brand names Semanext and Livarise under a deal announced March 17, 2026 ^[8].

Competition moved fast. IQVIA reported that Indian prices had already fallen by up to 90% ^[4]. Novo Nordisk responded by cutting its own prices and using partnerships to defend its Indian market share after the generics launched ^[9]. The Indian semaglutide market is estimated at $1 billion over the next two years, in a country with more than 100 million people with diabetes and another 136 million who are pre-diabetic ^[8].

India regulates semaglutide copies as “similar biologics,” which requires local Phase III-style clinical trials ^[4]. These prices are Indian domestic prices and are not available to US buyers.

What happened in Canada?

Canada’s path was unusual. Novo Nordisk’s core Canadian compound patent, CA 2,601,784, lapsed in 2019 after maintenance fees went unpaid ^[7]. Canadian data exclusivity expired on January 4, 2026 ^[7]. Because the compound patent is absent from Canada’s Patent Register, generic applicants there avoid the PM(NOC) linkage system and its typical 24-month litigation stay ^[7].

The approvals then came quickly:

• April 28, 2026: Canada became the first G7 country to approve a generic version of semaglutide, through Health Canada ^[5][21].
• May 1, 2026: Health Canada authorized a second generic, from Apotex — a generic of Ozempic for once-weekly treatment of adults with type 2 diabetes — and said seven other submissions were under review ^[5].
• Mid-May 2026: Apotex launched Apo-Semaglutide Injection ^[6].
• May 21, 2026: Hims & Hers began offering the Apotex generic in Canada, its first international generic GLP-1, with plans starting at C$149 per month ^[6].
• June 30, 2026: Health Canada approved the first generic semaglutide for weight loss ^[22].
• September 18, 2026: Health Canada granted Sandoz Canada authorization to market PrSandoz Semaglutide, a generic version of Ozempic for the once-weekly treatment of adults with type 2 diabetes, issued for three doses delivered subcutaneously via two pen presentations; Sandoz Canada is taking the necessary steps to prepare for future commercialization ^[25].

Dr Reddy’s also received Canadian approval in April 2026 and launched its generic in the country ^[6].

On price, brand-name Ozempic in Canada runs between C$200 and C$400 per month depending on dose, region, and insurance ^[6]. Sandoz has pledged generic pricing up to 70% below the brand, which could bring monthly costs from roughly CAD 1,000 down to CAD 300 or less ^[7]. Health Canada notes that many generic medications in Canada are 45% to 90% cheaper than the brand-name versions ^[5]. These are Canadian prices for the Canadian market, not prices available to US buyers.

Is generic semaglutide a generic or a biosimilar?

In the US, it would be a generic. The FDA treats peptide chains of fewer than 40 amino acid residues as drugs eligible for the generic ANDA pathway, and semaglutide, at 31 amino acids, qualifies — as does tirzepatide, at 39 amino acids ^[3][4].

Other regulators draw the line differently. Under current European Medicines Agency rules, synthetically made semaglutide would be treated as a generic and recombinant semaglutide as a biosimilar ^[4]. Canada and Saudi Arabia treat semaglutide as a chemical drug regardless of how it is made, requiring only bioequivalence studies ^[4]. India classifies it as a biologic and requires local trials ^[4].

Health Canada describes its approved generics as “complex synthetic products that are pharmaceutically equivalent to the brand name biologic drug” ^[5]. Novo Nordisk makes semaglutide using recombinant yeast fermentation followed by solid-phase synthesis, while generic versions are more likely to be made through entirely synthetic methods ^[3].

Who is preparing to sell generic semaglutide?

IQVIA has identified more than 70 integrated pharma companies applying for marketing authorization, plus about 70 additional companies able to manufacture semaglutide active ingredient for third parties ^[4].

In China, 17 candidates have reached Phase 3 clinical trials or the premarket application stage ^[3]. At least 10 Indian generics firms have approached India’s regulator for permission to run human clinical trials on semaglutide ^[3]. Named players include Dr Reddy’s, Lupin, Alkem, Biocon, Sun Pharma, Jiangsu Hengrui, Sandoz, and Brazil’s Biomm ^[3].

In Canada, abbreviated new drug submissions have been under review from Sandoz Canada, Apotex, and Hikma, and Vimy Pharma has announced plans for a domestically manufactured Canadian generic ^[7]. Bachem, a peptide manufacturer, is expanding capacity in Switzerland to meet semaglutide-era demand ^[3].

Is compounded semaglutide the same as a generic?

No. Compounded semaglutide products are copycat versions made by compounding pharmacists. They are not considered true generics because they have not been reviewed or approved by the FDA for safety or effectiveness ^[2]. The FDA has increasingly cracked down on them and has proposed limits on how much compounding pharmacists can produce ^[2].

Drugs.com also warns that fraudulent online pharmacies may attempt to sell an illegal “generic version of Ozempic,” and that such products may be counterfeit and potentially unsafe ^[1].

What can US patients do about price before generics arrive?

Ozempic can cost close to $1,000 a month in the US ^[2]. Novo Nordisk has introduced a cash price of $349 a month for Ozempic through its NovoCare price guide — a self-pay price, not the list price and not what an insured patient pays ^[2].

Separately, Novo Nordisk announced in February 2026 that it will cut the monthly US list prices of Ozempic and Wegovy to $675 starting in 2027 ^[2][20]. NBC News, reporting on May 13, 2026, described the cut as taking effect starting next year ^[2]. A list price is the manufacturer’s posted price, not what a patient actually pays at the pharmacy.

Even with the lower cash price, NBC News reports that many patients still struggle to afford the drug without insurance ^[2].

Can Americans order generic semaglutide from Canada or India?

The published record does not support that as a practical route. The first Canadian generic approvals — from Apotex and Dr Reddy’s — were authorized only for managing type 2 diabetes in adults ^[5][6]. Indian prices and Canadian prices apply to those domestic markets.

Commentators have noted that Canadian generic entry could create pressure through US importation programs under Section 804 of the Federal Food, Drug, and Cosmetic Act ^[7]. Drugs.com’s consumer guidance documents the counterfeit risk from online pharmacies that are not reputable, warning that products sold as “generic Ozempic” may be counterfeit and potentially unsafe ^[1].

What could move the US date earlier or later?

The biggest variable is the secondary patent portfolio. I-MAK’s projection is that Novo Nordisk’s 49-plus semaglutide patents could push US generic entry as far out as 2042 ^[2]. That is an advocacy-group forecast, not a settled outcome.

Other factors cut both ways. Novo Nordisk’s strategy may pivot toward next-generation GLP-1 therapies such as CagriSema and oral semaglutide variants ^[7]. European markets in the second wave — the Baltics and parts of Central and Eastern Europe — lose exclusivity before the US, giving generic makers a proving ground ^[4]. Generic makers also face technical hurdles, including peptide stability and device compatibility ^[7].

The FDA held a two-day workshop on September 23 and 24, 2026 on navigating the GLP-1 generic drug pathway, addressing key product development and regulatory assessment considerations for generic GLP-1 agonist products, including the critical quality attributes of recombinant and synthetic peptides and the challenges of drug-device combination products ^[26].

Is there a generic version of Wegovy?

Not in the US. Wegovy contains the same active ingredient as Ozempic — semaglutide — and experts quoted by NBC News do not expect generic semaglutide in the US until at least the end of 2031 ^[2]. Canada approved its first generic semaglutide for weight loss on June 30, 2026 ^[22], but that approval applies to the Canadian market only.

Mylan Pharmaceuticals launched a lawsuit in Delaware federal court on September 24, 2026, asking for a finding that its proposed generic version of Wegovy does not infringe a Novo Nordisk patent — the latest salvo in a larger intellectual property fight over the GLP-1 ^[27].

How much cheaper will generics be?

The track record elsewhere gives a sense of the range. Nilaya Varma, cofounder of the consulting firm Primus Partners, told C&EN that generic entry could lower costs by 80% in some cases ^[3]. IQVIA reported Indian prices had already fallen by up to 90% ^[4]. Health Canada says many Canadian generics are 45% to 90% cheaper than brands ^[5], and Sandoz has pledged Canadian pricing up to 70% below brand ^[7].

Sources

1. Drugs.com. Generic Ozempic availability. August 13, 2026.
2. NBC News. Cheaper generic Ozempic is coming soon — but not for Americans. Here’s why. May 13, 2026.
3. Chemical & Engineering News. Looming GLP-1 drug patent expirations draw generics firms. December 9, 2025.
4. IQVIA. Your questions answered: Off-patent semaglutide in 2026. April 7, 2026.
5. Health Canada. Canada approves second generic semaglutide, the first G7 country to do so. May 1, 2026.
6. Reuters. Hims offers Apotex’s generic semaglutide in Canada after Novo patent expiry. May 21, 2026.
7. Patent Lawyer Magazine. The semaglutide saga continues: navigating generic entry and reinforcing patent strategies in Canada. November 14, 2025.
8. Pearce IP. Generic semaglutide launches in India, including by Dr Reddy’s, Zydus, Alkem, Sun Pharma & Glenmark. March 21, 2026.
9. CNBC. India is launching cheap weight-loss drugs — but Novo Nordisk is betting its brands will stay on top. March 23, 2026.
10. ThePrint. Indian manufacturers kick off generic semaglutide price war.
11. Reuters. FDA set to review Sandoz’s generic GLP-1s. June 29, 2026.
12. Drug Topics. FDA accepts Sandoz applications for generic tirzepatide. July 3, 2026.
13. Managed Healthcare Executive. Teva launches first generic GLP-1 drug for obesity. August 28, 2025.
14. SingleCare. Generic GLP-1 medications: Current and future landscape.
15. Meto. Semaglutide patent expiry: What biosimilars mean for you. June 9, 2026.
16. The White House. Fact sheet: President Donald J. Trump announces major developments in bringing most-favored-nation pricing to American patients. November 6, 2025.
17. Drugs.com. How much does Foundayo cost? July 22, 2026.
18. Fierce Pharma. The oral GLP-1 tracker: Novo’s Wegovy pill, Lilly’s Foundayo continue prescription climb. September 11, 2026.
19. Teva. Teva announces FDA approval and launch of generic Saxenda (liraglutide injection) — first generic GLP-1 indicated for weight loss. August 28, 2025.
20. Novo Nordisk. Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus (semaglutide medicines), building on continued efforts to expand access.
21. Health Canada. Canada becomes the first G7 country to approve a generic version of semaglutide. April 28, 2026.
22. Health Canada. Canada approves first generic semaglutide for weight loss. June 29, 2026.
23. NovoCare. Wegovy (semaglutide) cost, coverage, and savings resources.
24. LillyDirect. Foundayo (orforglipron): Now available.
25. BioSpace. Sandoz Canada receives Health Canada regulatory approval for (Pr)Sandoz® Semaglutide, a generic version of (Pr)Ozempic®. September 18, 2026.
26. FDA. FDA/Center for Research on Complex Generics (CRCG) Workshop on Navigating the GLP-1 Generic Drug Pathway. September 23, 2026.
27. Law360. Mylan Wants Del. Judge To Clear Wegovy Generic Drug. September 24, 2026.